Meeting
2024 ASCO Genitourinary Cancers Symposium
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
Authors
Loic Djaileb
Ahmanson Translational Theranostics Division, University of California, Los Angeles, Los Angeles, CA
Loic Djaileb , Wesley Robert Armstrong , Daniel Thompson , Andrei Gafita , Andrea Farolfi , Matthew R. Cooperberg , Peter Carroll , Samuel L. Washington III, Robert Evan Reiter , Matthias Eiber , Ken Herrmann , Wofgang P Fendler , Johannes Czernin , Thomas A. Hope , Jeremie Calais
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT03368547, NCT02611882, NCT02919111
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 285)
DOI
10.1200/JCO.2024.42.4_suppl.285
Abstract #
285
Poster Bd #
L20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
First Author: Loic Djaileb
Poster
2021 ASCO Annual Meeting
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
First Author: Frederic Pouliot
Poster
2019 ASCO Annual Meeting
Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.
First Author: Jeremie Calais